tiprankstipranks
Trending News
More News >
Addex Therapeutics Ltd (ADR) (ADXN)
:ADXN
Advertisement

Addex Therapeutics (ADXN) Price & Analysis

Compare
76 Followers

ADXN Stock Chart & Stats


Addex Therapeutics News

ADXN FAQ

What was Addex Therapeutics Ltd (ADR)’s price range in the past 12 months?
Addex Therapeutics Ltd (ADR) lowest stock price was $6.51 and its highest was $11.84 in the past 12 months.
    What is Addex Therapeutics Ltd (ADR)’s market cap?
    Addex Therapeutics Ltd (ADR)’s market cap is $13.35M.
      When is Addex Therapeutics Ltd (ADR)’s upcoming earnings report date?
      Addex Therapeutics Ltd (ADR)’s upcoming earnings report date is Sep 01, 2025 which is 7 days ago.
        How were Addex Therapeutics Ltd (ADR)’s earnings last quarter?
        Currently, no data Available
        Is Addex Therapeutics Ltd (ADR) overvalued?
        According to Wall Street analysts Addex Therapeutics Ltd (ADR)’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Addex Therapeutics Ltd (ADR) pay dividends?
          Addex Therapeutics Ltd (ADR) does not currently pay dividends.
          What is Addex Therapeutics Ltd (ADR)’s EPS estimate?
          Addex Therapeutics Ltd (ADR)’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Addex Therapeutics Ltd (ADR) have?
          Addex Therapeutics Ltd (ADR) has 1,536,287 shares outstanding.
            What happened to Addex Therapeutics Ltd (ADR)’s price movement after its last earnings report?
            Currently, no data Available
            Which hedge fund is a major shareholder of Addex Therapeutics Ltd (ADR)?
            Among the largest hedge funds holding Addex Therapeutics Ltd (ADR)’s share is New Leaf Venture Partners, L.L.C.. It holds Addex Therapeutics Ltd (ADR)’s shares valued at 0.

              Company Description

              Addex Therapeutics Ltd (ADR)

              Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot–Marie–Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.

              Addex Therapeutics (ADXN) Earnings & Revenues

              ADXN Earnings Call

              Q1 2025
              0:00 / 0:00
              Earnings Call Sentiment|Neutral
              The earnings call highlighted significant strategic partnerships and advancements in drug development programs, notably the successful Series A financing for Neurosterix and progress in the GABAB PAM program. However, challenges remain with decreased income and cash limitations for unpartnered programs, indicating a balanced outlook.View all ADXN earnings summaries
              Similar Stocks
              Company
              Price & Change
              Follow
              Plus Therapeutics
              Eterna Therapeutics
              Minerva Neurosciences
              GeoVax Labs
              Moleculin Biotech

              Ownership Overview

              0.07%99.93%
              Insiders
              Mutual Funds
              0.07% Other Institutional Investors
              99.93% Public Companies and
              Individual Investors

              Options Prices

              Currently, No data available
              ---
              Popular Stocks
              What am I Missing?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis